Doptelet

Drug Dova Pharmaceuticals
Total Payments
$7.1M
Transactions
16,429
Doctors
6,643
Companies
5

Payment Trends by Year

Year Amount Transactions Doctors
2023 $1.8M 5,412 3,076
2022 $58,130 20 10
2021 $1.4M 4,305 2,115
2020 $1.4M 2,404 1,224
2019 $2.0M 3,300 1,832
2018 $367,154 988 717

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $2.8M 382 39.8%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2.4M 738 33.9%
Consulting Fee $892,446 334 12.5%
Food and Beverage $417,097 14,024 5.9%
Travel and Lodging $218,175 597 3.1%
Grant $200,650 5 2.8%
Space rental or facility fees (teaching hospital only) $126,181 48 1.8%
Education $16,978 301 0.2%

Payments by Type

General
$4.3M
16,047 transactions
Research
$2.8M
382 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A 3-period, 2-sequence, Randomized, Open-label, Partial Replicate Study to Evaluate the Bioequivalence of 2 Lots of Avatrombopag 20 mg Oral Tablets (Test and Reference) Administered as a Single Dose in Healthy Adult Subjects under the Fed Condition Dova Pharmaceuticals $674,854 0
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Avatrombopag for Persistent Chemotherapy-Induced Thrombocytopenia in Patients with Gastrointestinal Malignancies SOBI, INC $547,060 0
Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding. Dova Pharmaceuticals $372,999 1
A Single-dose, Six-sequence Cross-over Study to Compare the Relative Oral Bioavailability of and Food Effect on a Pediatric Age-Appropriate Avatrombopag Formulation Compared to the Commercial Tablet Formulation in Healthy Adult Subjects Under Fed and Fasted Conditions. Dova Pharmaceuticals $353,975 0
Randomized, Double-blind, Placebo-controlled Study With Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for greater than or equal to 6 Months Dova Pharmaceuticals $346,492 0
Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung (small cell and non-small cell) and bladder cancer. Dova Pharmaceuticals $201,615 0
An Observational Cohort Study of the Use of Avatrombopag in Patients With Thrombocytopenia Associated With Chronic Liver Disease Undergoing a Procedure Dova Pharmaceuticals $110,148 0
An Open-Label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Subjects with Thrombocytopenia Scheduled for a Surgical Procedure Dova Pharmaceuticals $96,449 0
Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim Dova Pharmaceuticals $90,208 0
Open-label multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding Dova Pharmaceuticals $41,597 0

Top Doctors Receiving Payments for Doptelet

Doctor Specialty Location Total Records
Unknown — Austin, TX $3.2M 437
, M.D Specialist Canton, OH $194,089 151
, MD Medical Oncology Dallas, TX $166,746 101
, M.D Student in an Organized Health Care Education/Training Program Charlottesville, VA $145,560 96
, M.D Hematology & Oncology Miami, FL $131,028 88
, MD Medical Oncology Fort Myers, FL $101,290 65
, M.D Internal Medicine Los Angeles, CA $83,986 94
, M.D Medical Oncology Bethesda, MD $77,370 35
, MD Pediatric Hematology-Oncology Peoria, IL $75,087 35
, MD Transplant Surgery Los Angeles, CA $74,636 67
, MD Medical Oncology Grosse Pointe Woods, MI $70,763 47
, MD Hematology & Oncology Atlanta, GA $66,413 31
, M.D Hematology Jacksonville, FL $63,136 45
, MD DPHIL Internal Medicine Charlestown, MA $63,007 20
, M.D, Internal Medicine Los Angeles, CA $56,463 30
, MD Hematology & Oncology Towson, MD $53,480 33
, M.D Hematology & Oncology Chandler, AZ $53,186 34
, M.D Hematology & Oncology Livingston, NJ $52,501 38
, M.D Hematology Seattle, WA $51,834 29
, MD Hematology & Oncology Fort Myers, FL $50,179 31
, MD Hematology & Oncology Boston, MA $49,295 24
, MD Hematology & Oncology Cleveland, OH $43,572 19
, MD Student in an Organized Health Care Education/Training Program Cerritos, CA $42,107 46
, D.O Specialist Voorhees, NJ $42,082 26
, MD Pediatrics New York, NY $40,918 18
123…266»

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $7.1M
  • Total Doctors 6,643
  • Transactions 16,429

About Doptelet

Doptelet is a drug associated with $7.1M in payments to 6,643 healthcare providers, recorded across 16,429 transactions in the CMS Open Payments database. The primary manufacturer is Dova Pharmaceuticals.

Payment data is available from 2018 to 2023. In 2023, $1.8M was paid across 5,412 transactions to 3,076 doctors.

The most common payment nature for Doptelet is "Unspecified" ($2.8M, 39.8% of total).

Doptelet is associated with 10 research studies, including "A 3-period, 2-sequence, Randomized, Open-label, Partial Replicate Study to Evaluate the Bioequivalence of 2 Lots of Avatrombopag 20 mg Oral Tablets (Test and Reference) Administered as a Single Dose in Healthy Adult Subjects under the Fed Condition" ($674,854).